Article Details

Sun Pharma Acquires Checkpoint Therapeutics for $355 Million

Retrieved on: 2025-03-10 18:15:51

Tags for this article:

Click the tags to see associated articles and topics

Sun Pharma Acquires Checkpoint Therapeutics for $355 Million. View article details on hiswai:

Summary

The article discusses Sun Pharma's acquisition of Checkpoint Therapeutics, focusing on the key biotech advancement of their FDA-approved drug, Unloxcyt (cosibelimab-ipdl) for treating cutaneous squamous cell carcinoma. This highlights cancer immunotherapy developments and market dynamics in the biotech sphere.

Article found on: www.pharmexec.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up